| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PAFAD; PAFAH; LP-PLA2; LDL-PLA2 |
| Entrez GeneID | 7941 |
| clone | 3E1G5 |
| WB Predicted band size | 50kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PLA2G7 (AA: 22-441) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于**PLA2G7抗体**的3篇参考文献示例(部分信息为模拟，建议通过数据库核实)：
---
1. **文献名称**: *Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target for cardiovascular disease*
**作者**: Wilensky RL, et al.
**摘要**: 该研究探讨了PLA2G7(Lp-PLA2)在动脉粥样硬化中的促炎作用，并评估了特异性单克隆抗体对PLA2G7的抑制作用。结果显示，抗体可显著降低氧化磷脂的生成，抑制斑块炎症反应，提示其作为心血管疾病治疗靶点的潜力。
2. **文献名称**: *Development of a high-sensitivity ELISA for Lp-PLA2 activity using monoclonal antibodies*
**作者**: Thompson A, et al.
**摘要**: 作者开发了一种基于PLA2G7单克隆抗体的高灵敏度ELISA检测方法，用于量化人血浆中Lp-PLA2的活性。该方法在临床样本中验证了PLA2G7水平与冠心病风险的相关性，为疾病诊断提供了新工具。
3. **文献名称**: *Anti-PLA2G7 autoantibodies in autoimmune diseases: Association with disease activity*
**作者**: Bhatia V, et al.
**摘要**: 研究分析了系统性红斑狼疮(SLE)和类风湿关节炎患者血清中抗PLA2G7自身抗体的水平，发现其与疾病活动度呈正相关，提示PLA2G7抗体可能参与自身免疫病理过程，或作为生物标志物。
---
**注**：以上文献信息为示例，实际引用时请通过PubMed、Web of Science等平台核实具体作者、标题及摘要内容，并补充DOI或期刊信息。
The phospholipase A2 group VII (PLA2G7) antibody targets the protein encoded by the PLA2G7 gene, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2) or platelet-activating factor acetylhydrolase (PAF-AH). This enzyme hydrolyzes oxidized phospholipids in low-density lipoproteins (LDL), generating pro-inflammatory mediators like lysophosphatidylcholine and oxidized free fatty acids, which contribute to vascular inflammation and atherosclerosis. PLA2G7 is primarily secreted by macrophages and circulates bound to lipoproteins, making it a biomarker for cardiovascular disease risk.
PLA2G7 antibodies are essential tools in research and diagnostics, enabling quantification and localization of the enzyme in tissues and biological fluids. They are used in techniques such as ELISA, Western blotting, and immunohistochemistry to study PLA2G7's role in atherosclerosis, Alzheimer’s disease, and other inflammatory conditions. Elevated Lp-PLA2 levels correlate with increased risk of stroke and coronary artery disease, driving interest in therapeutic inhibition. However, PLA2G7's dual role—anti-inflammatory in degrading platelet-activating factor (PAF) versus pro-inflammatory in plaque destabilization—complicates its clinical interpretation. Antibodies help clarify these mechanisms by assessing expression patterns, activity modulation, and interactions with pharmacological inhibitors. Commercial PLA2G7 antibodies are typically validated for specificity across human and model organism samples, supporting both basic research and drug development targeting inflammatory pathways.
×
